CuII-VLIH
Financiado
Copper(II) Induced Oxidation of Enolates via Visible Light Induced Homolysis
CuII-VLIH is envisaged and designed to develop novel synthetic strategies to access a wide variety of bioactive cyclic and acyclic 1,4-dicarbonyl organic compounds via Cu(II) mediated oxidation of enolates using visible light indu...
CuII-VLIH is envisaged and designed to develop novel synthetic strategies to access a wide variety of bioactive cyclic and acyclic 1,4-dicarbonyl organic compounds via Cu(II) mediated oxidation of enolates using visible light induced homolysis (VLIH). Considering the earth abundance and low cost, Cu(II)-based complexes are recently being utilized as efficient photocatalysts and as low-cost alternative to the Ru or Ir-based complexes. A range of Cu(II)-complexes will be screened in the proposed work for optimizing the efficiency of the aforementioned enolate oxidation processes via photoredox catalysis. The most effective catalyst will oxidatively activate the substrates and the reactions will proceed through the generation of photoinduced reactive species (enol radicals) that can be productively exploited for the synthesis of a range of biologically significant dicarbonyl compounds by successive reaction with an alkene acceptor followed by quenching with molecular oxygen. CuII-VLIH will address the long-standing problem of finding an appropriate classical activation mode for different varieties of enolizable ketones by providing a remarkable activation mode through the formation of enol radical intermediates. CuII-VLIH also aims to bridge the gap between the fields of medicine and energy by enabling facile and highly selective synthesis of a wide array of high value heterocyclic moieties by utilizing copper complexes as environmentally benign photoredox catalysts and visible light as a sustainable source of energy. The successful photoactivation of enolates and subsequent combination of enol radical with suitable alkene acceptors in the presence of molecular oxygen would also allow synthesis of various carbocyclic and heterocyclic natural products such as convulatamydine A and pharmaceutically relevant compounds like AG-041R, serotonin 5HT1A receptor antagonist via late-stage modifications.
ver más
Duración del proyecto: 23 meses
Fecha Inicio: 2022-09-01
Fecha Fin: 2024-08-31
Fecha Fin: 2024-08-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-08-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-MSCA-2021-PF-01-01:
MSCA Postdoctoral Fellowships 2021
Cerrada
hace 3 años
Líder del proyecto
HOCHSCHULE FUR ANGEWANDTE WISSENSCHAFTEN MUNC...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5